GLP-1 / Metabolic injectable

Mazdutide

By Hack SmithLast updated: How we research

Dual-action peptide for significant weight loss

Common Uses
  • Weight Loss/Fat Loss (GLP)
Evidence Grade
A — Strong — Human clinical trial data
Human randomized controlled trial data available.
Safety Notes

Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — based on GLP-1 agonist class labeling Discontinue immediately if pancreatitis is suspected (persistent severe abdominal pain) Significant lean mass/muscle loss may occur with rapid weight reduction — resistance training and adequate protein intake strongly recommended Use with caution in patients with history of gastroparesis or severe GI disease

Mechanism of Action

Mazdutide (also known as IBI362 or LY3305677) is a dual agonist that activates both glucagon-like peptide-1 (GLP-1) receptors and glucagon receptors. GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses appetite, and slows gastric emptying, while glucagon receptor activation increases energy expenditure and promotes hepatic lipid oxidation. This dual mechanism creates complementary effects on both caloric intake reduction and metabolic rate enhancement. Key Pathways: GLP-1 receptor signaling (appetite suppression, insulin secretion, delayed gastric emptying), Glucagon receptor signaling (increased energy expenditure, hepatic lipid metabolism), Incretin-mediated glucose homeostasis The combined GLP-1 and glucagon receptor activation translates to significant weight loss (up to 14% at 48 weeks) and meaningful reductions in HbA1c (1.4-1.7%) in clinical trials. Patients also experience improvements in cardiometabolic markers including blood pressure, cholesterol, and triglycerides, reflecting the compound's broad metabolic effects beyond weight reduction alone.

Common Dose Reference Ranges

Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.

Low
1.5
mg
Standard
3
mg
High
9
mg
🔬 Related compounds
RetatrutideOrforglipronSemaglutideTirzepatideSurvodutide
🔒 Skool Members Only

Full Mazdutide protocols — frequency, timing, cycle length, reconstitution & research

Frequency: Once weekly
Half-life: approximately 100-150 hours (estimated 4-6 days)
Cycle length: 16 weeks
Side Effects
  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
  • Gastroparesis risk / Delayed gastric emptying
  • Muscle loss without resistance training
  • Pancreatitis
Compatible Stacks
Join Skool to unlock full Mazdutide data →